EPISODE · Jun 14, 2025 · 13 MIN
EHA 2025: MaaT Pharma presented an update for its microbiome based treatment for GVHD, Xervyteg, which it has now filed for approval with the EMA
from BiotechTV - News · host BiotechTV
CMO Gianfranco Pittari walks us through data from the pivotal ARES study that MaaT announced in January and filed with the EMA. Plus, an EHA presentation from an early access program that is a follow-up from data we saw in ASH in December.
Embed this episode
NOW PLAYING
EHA 2025: MaaT Pharma presented an update for its microbiome based treatment for GVHD, Xervyteg, which it has now filed for approval with the EMA
0:00
13:09
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 13 minutes long.
When was this BiotechTV - News episode published?
This episode was published on June 14, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!